{
  "ticker": "REGN",
  "company_name": "Regeneron Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03645746",
      "title": "Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteer",
      "start_date": "2018-08-23",
      "completion_date": "2019-09-30",
      "enrollment": 0,
      "sponsor": "Regeneron Pharmaceuticals"
    },
    {
      "nct_id": "NCT04180488",
      "title": "Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are na\u00efve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Chronic Spontaneous Urticaria",
      "start_date": "2019-12-11",
      "completion_date": "2024-10-25",
      "enrollment": 0,
      "sponsor": "Sanofi"
    },
    {
      "nct_id": "NCT03132636",
      "title": "PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Carcinoma, Basal Cell",
      "start_date": "2017-06-29",
      "completion_date": "2023-04-27",
      "enrollment": 0,
      "sponsor": "Regeneron Pharmaceuticals"
    },
    {
      "nct_id": "NCT02057250",
      "title": "To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "RA",
      "start_date": "2014-03",
      "completion_date": "2016-03",
      "enrollment": 0,
      "sponsor": "Sanofi"
    },
    {
      "nct_id": "NCT05785767",
      "title": "A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Advanced Non-Small Cell Lung Cancer",
      "start_date": "2023-06-30",
      "completion_date": "2032-02-05",
      "enrollment": 0,
      "sponsor": "Regeneron Pharmaceuticals"
    },
    {
      "nct_id": "NCT03022292",
      "title": "The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy",
      "status": "COMPLETED",
      "phase": "PHASE4",
      "condition": "Wet Macular Degeneration",
      "start_date": "2017-03-30",
      "completion_date": "2020-08-31",
      "enrollment": 0,
      "sponsor": "University of California, Los Angeles"
    },
    {
      "nct_id": "NCT03161912",
      "title": "A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Macular Edema",
      "start_date": "2017-11-24",
      "completion_date": "2021-12-17",
      "enrollment": 0,
      "sponsor": "Bayer"
    },
    {
      "nct_id": "NCT03738423",
      "title": "Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Atopic Dermatitis",
      "start_date": "2018-11-13",
      "completion_date": "2020-07-24",
      "enrollment": 0,
      "sponsor": "Regeneron Pharmaceuticals"
    },
    {
      "nct_id": "NCT06352073",
      "title": "Dupilumab for Eosinophilic Esophagitis With Severe Strictures",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE4",
      "condition": "Eosinophilic Esophagitis, EoE",
      "start_date": "2024-05-16",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "University of North Carolina, Chapel Hill"
    },
    {
      "nct_id": "NCT05685173",
      "title": "A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "B-cell Non-Hodgkins Lymphoma (B-NHL)",
      "start_date": "2023-04-12",
      "completion_date": "2029-05-16",
      "enrollment": 0,
      "sponsor": "Regeneron Pharmaceuticals"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1": 14,
      "PHASE3": 6,
      "PHASE2": 12,
      "PHASE2, PHASE3": 2,
      "PHASE4": 5,
      "": 7,
      "PHASE1, PHASE2": 2,
      "NA": 1,
      "EARLY_PHASE1": 1
    },
    "by_status": {
      "COMPLETED": 31,
      "ACTIVE_NOT_RECRUITING": 4,
      "TERMINATED": 5,
      "ENROLLING_BY_INVITATION": 1,
      "RECRUITING": 6,
      "APPROVED_FOR_MARKETING": 1,
      "UNKNOWN": 1,
      "NOT_YET_RECRUITING": 1
    },
    "active_trials": 11,
    "completed_trials": 31,
    "conditions": [
      "Advanced Non-Small Cell Lung Cancer",
      "Age Related Macular Degeneration, Pigment Epithelial Detachment",
      "Age-Related Macular Degeneration",
      "Ankylosing Spondylitis",
      "Atopic Dermatitis",
      "Atopic Dermatitis (AD)",
      "Atopic Dermatitis, Ichthyosis, Psoriasis",
      "B-cell Non-Hodgkins Lymphoma (B-NHL)",
      "Carcinoma, Basal Cell",
      "Chronic Obstructive Pulmonary Disease",
      "Chronic Spontaneous Urticaria",
      "Colorectal Neoplasms, Neoplasm Metastasis",
      "Diabetic Macular Edema",
      "Diabetic Nephropathies, Diabetic Glomerulosclerosis",
      "Eosinophilic Esophagitis, EoE",
      "Follicular Lymphoma, Lymphoma",
      "Gout",
      "Healthy",
      "Healthy Volunteer",
      "Healthy Volunteers",
      "Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",
      "Hypercholesterolaemia",
      "Hypercholesterolemia",
      "Hypercholesterolemia, Acute Coronary Syndrome",
      "Hypertriglyceridemia",
      "Intraocular Inflammation, Suspected Endophthalmitis",
      "Lung Cancer",
      "Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific",
      "Macular Edema",
      "Metabolic Dysfunction-associated Steatohepatitis (MASH)",
      "Metastatic Castration-resistant Prostate Cancer",
      "Multiple Myeloma",
      "Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia",
      "Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC)",
      "Non-small Cell Lung Cancer",
      "Osteoarthritis, Knee, Osteoarthritis, Hip",
      "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "Prostatic Neoplasms, Neoplasm Metastasis",
      "RA",
      "Relapsed and Refractory Multiple Myeloma (RRMM)",
      "Retinal Vein Occlusion",
      "Rheumatoid Arthritis",
      "Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma",
      "Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage",
      "Wet Macular Degeneration"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:25.515761",
    "search_query": "Regeneron Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Regeneron+Pharmaceuticals,+Inc."
  }
}